Previous Article | Next Article 
Journal of Clinical Microbiology, September 2005, p. 4649-4653, Vol. 43, No. 9
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.9.4649-4653.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Increased Genetic Diversity of Neisseria meningitidis Isolates after the Introduction of Meningococcal Serogroup C Polysaccharide Conjugate Vaccines
Mathew A. Diggle1 and
Stuart C. Clarke1,2*
Scottish Meningococcus and Pneumococcus Reference Laboratory, Stobhill Hospital, Glasgow G21 3UW, United Kingdom,1
Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, United Kingdom2
Received 14 January 2005/
Returned for modification 7 March 2005/
Accepted 4 May 2005

ABSTRACT
During the 1990s, the incidence of meningococcal disease was
high in the United Kingdom. This was due primarily to an increase
in serogroup C disease, particularly that within the ET-37/ST-11
genetic lineage. Serogroup C meningococcal polysaccharide conjugate
vaccines were introduced in the United Kingdom in 1999, but
the sequence types of meningococci causing disease since that
time have not yet been reported. We have used serogrouping and
multilocus sequence typing to characterize meningococci from
patients with invasive disease over a 4-year period and show
that there is a significant increase in genetic diversity but
no genetic evidence of capsule switching.

INTRODUCTION
Polysaccharide conjugate vaccines are providing essential and
highly effective immunization against some of the major human
pathogens (
1,
13,
19,
20,
24). One such pathogen,
Neisseria meningitidis, remains an important cause of meningitis and septicemia
worldwide (
23). Serogroup C meningococcal disease became a particular
problem in the United Kingdom during the 1990s and was associated
with a high prevalence of the ET37/ST11 clone (
6,
16). Prospective
enhanced surveillance of those meningococci associated with
throat carriage and invasive disease was initiated in the United
Kingdom before the implementation of the meningococcal serogroup
C conjugate (MenC) vaccines towards the end of 1999 (
2,
5,
13).
An overall vaccine uptake of 85% was achieved in the United
Kingdom for the whole population under 20 years of age (
14),
and the implementation of MenC vaccines has led to a reduced
level of serogroup C meningococcal throat carriage and also
a reduced level of invasive disease (
13,
14,
17,
18). However,
since the population dynamics of meningococcal disease are very
fluid, with serogroup B and serogroup C historically undergoing
a complementary cyclic pattern (
7,
16), it is essential to understand
the intra- and interlineage population dynamics of this disease.
We used multilocus sequence typing (MLST) to characterize a
collection of 432 meningococci, isolated from cases of invasive
meningococcal disease before (1999) and during (2000, 2001,
and 2002) the introduction of MenC vaccines (years 1 to 4) in
Scotland.

MATERIALS AND METHODS
Four hundred thirty-two isolates of
N. meningitidis from patients
with invasive meningococcal disease in Scotland were analyzed
between 1999 and 2002 inclusive by MLST, a method which sequences
internal fragments of seven housekeeping genes (
6,
12). These
isolates were isolated from normally sterile sites (blood and
cerebrospinal fluid) from patients with meningococcal disease
from all 15 National Health Service boards via their representative
diagnostic hospital laboratories. Phenotypic and genotypic characterization
followed by assignment of nucleotide sequence data to sequence
types (STs) and complexes was performed as previously described
(
4,
6-
8). Briefly, internal fragments of seven housekeeping
genes
abcZ,
adk,
aroE,
fumC,
gdh,
pdhC, and
pgmwere
sequenced using an automated protocol with a Roboseq 4200 (MWG
Biotech UK Ltd., Milton Keynes, United Kingdom) and MegaBACE
1000 DNA sequencer (Amersham Biosciences, Little Chalfont, United
Kingdom). Alleles were assigned by comparing nucleotide sequence
data at that locus to all known alleles at that locus. STs were
assigned according to the combination of the seven alleles with
reference to the
N. meningitidis MLST database (
www.mlst.net).
Intra- and interlineage comparisons were made using the Sequence
Type Analysis and Recombinational Tests (START) suite of programs
available at
http://pubmlst.org/software/analysis/start (
10).
Mutation and/or recombination events were calculated by determining
the number of substitutions per nonsynonymous (
dN) and synonymous
(
dS) site within a particular nucleotide sequence from the allele
sequence using the method of Nei and Gojobori (
15), which is
included in the START software suite. A summary of the single
multilocus measure of linkage disequilibrium was achieved by
the index of association (
IA) (
3,
21) using the START program.

RESULTS
Sequence typing data from the 428 meningococci used in this
study show that the meningococcal population was highly diverse
and that an increasing trend of diversity was noted in individual
years, from years 1 to 4 (Fig.
1). The absolute numbers of meningococci
isolated in each year were 130 in 1999, 130 in 2000, 80 in 2001,
and 88 in 2002. The incidence of serogroup C meningococci decreased
during the study, from 58 (45%) in year 1 to 10 (11%) in year
4. The isolation of serogroup B meningococci also changed, resulting
in a slight increase from 65 (50%) in year 1 to 69 (78%) in
year 4. In year 1, serogroup C meningococci were assigned to
only five different STs; 95% of these STs were contained within
two complexes (ST-11 complex [93%] and ST-269 complex [2%])
(Table
1). Serogroup B meningococci were assigned to 31 different
STs; 68% of these STs were contained within five complexes (ST-44
complex [34%], ST-269 complex [18%], ST-18 complex [8%], ST-35
complex [5%], and ST-32 complex [3%]) (Table
1). However, the
serogroups associated with different STs changed between years
1 and 4, such that, in year 4, serogroup C meningococci were
assigned to only two different STs; all of these STs were contained
within two complexes (ST-11 complex [91%] and ST-269 complex
[9%]). Serogroup B meningococci were assigned to 40 different
STs; 68% of these STs were contained within five complexes (ST-269
complex [26%], ST-44 complex [19%], ST-32 complex [16%], ST-18
complex [4%], and ST-254 [3%]). Importantly, over the study
period, the serogroup C ET-37/ST-11 genetic lineage declined
substantially and there was no corresponding increase in serogroup
B of the ET-37/ST-11 genetic lineage. Moreover, there was no
development of capsule switch (i.e., change of serogroup within
the same ST) as determined by serogroup and ST association.
Analysis of allele frequency showed that the number of alleles
present at each locus for each of the 4 years ranged between
eight for
adk (adenylate kinase) in year 1 and 20 for
aroE (shikimate
dehydrogenase) in year 4. The number of polymorphic sites present
at each locus for each year ranged between 14 in year 1 (3%
of sites for
adk) and 128 in year 4 (26% of sites for
aroE).
The number of alleles as a function of the number of isolates
indicated a clear correlation between the increase in the number
of alleles identified with an increase in the number of isolates
examined. This provides further evidence of meningococcal genetic
diversity within the 4 years of our study.
In year 1, disregarding serogroup, meningococci were assigned to 41 different STs within six distinct lineages. These lineages occurred between 1 (0.8%) and 55 (42%) times during year 1. In addition, there were 15 singleton types (11.5%) (i.e., no complex association). Isolates of the ST-11 complex accounted for 55 (42%) isolates and were assigned to two STs (ST-11 [n = 53] and ST-655 [n = 2]), the latter of which is a gdh (glucose-6-phosphate dehydrogenase) locus variant of ST-11. The ST-44 complex accounted for 22 isolates (17%), and these were divided into eight different STs; 14 were ST-41 (64%), 2 were ST-1097 (9%), and ST-44, -46, -146, -170, -1194 and -1255 were each represented by a single isolate (4.5%). In year 2, meningococci were assigned to 47 different STs, an increase of 13% from the previous year. They were further differentiated into nine distinct lineages, an increase of 33% from the previous year, with a 27% decrease in singleton representation. These lineages occurred between 1 (0.8%) and 49 (38%) times during year 2. This was statistically similar to the previous year (P = 0.714). Meningococci of the ST-11 complex continued to account for the majority (38%) of isolates. In year 3, meningococci were assigned to 47 different STs and were differentiated into eight different lineages, a decrease of 11% from the previous year, demonstrating an increase in ST diversity. These lineages occurred between 1 (1%) and 18 (23%) times during year 3. This range variation was significantly smaller (P = 0.0443). This highlights a significant decrease in the representation of multiple isolates and the subsequent increase in single represented isolates. Meningococci of the ST-11 complex continued to account for the majority (25%) of isolates. In year 4, meningococci were assigned 49 different STs, a 4% increase from the previous year and were differentiated into nine different lineages, an increase of 11% from year 3. These lineages occurred between 1 (1%) and 10 (11%) times, and the range of variation was therefore again smaller but not significantly so (P = 0.2621), resulting in a greater proliferation of different STs and thus a greater representation of single isolates. The ST-269 complex accounted for 17 isolates (19%), an increase of 12% from year 3. These were divided into 10 different STs which remained consistent. ST-269 and -275 accounted for four isolates (24%), ST-2205 accounted for two isolates (12%), with ST-13, -283, -467, -1095, -2157, -2166, -2205, and -2319 represented once (6%). Both ST-269 and -275 increased by 25% above year 3, and of the remaining STs, none had been represented in previous years. Interlineage variation accounted for 24 single-locus variations, a 140% increase, combined with 26 double-locus variations, an 8% increase, and 40 satellites, a decrease of 29% from year 3. The singletons accounted for 29 isolates (32%), an increase of 28% from the previous year. These were differentiated into 13 different STs, ST-11 (35%), ST-213 (24%), ST-1345 (7%), and ST-103, -136, -866, -1167, -1466, -2161, -2204, -2239, -231,7 and -2318 were represented once each (3.5%). ST-11 decreased by a further 44% from year 3.
Mutation and/or recombination events for the 432 isolates in this study, calculated using dN/dS ratios, showed that nonsynonymous nucleotide sequence changes were selected out of the population (Table 2). These data were compared to invasive meningococci contained within the global data set (http://neisseria.mlst.net). The data were comparable to the global data set, with only a few differences between the ratio values, except for aroE, suggesting that the proteins the genes encode are well conserved. The dN/dS ratio value was >1 for aroE, indicating that the proteins that these genes encode are not so well conserved and nonsynonymous changes were corrected faster than their occurrence by mutation. The index of association (IA) for the meningococcal population in years 1 to 4 was high (between 2.564 and 4.469), indicating a clonal population. However, the clonality reduced year by year in reflection of the reduction in serogroup C ST-11 strains.
View this table:
[in this window]
[in a new window]
|
TABLE 2. Natural selection and recombination in meningococci between 1999 and 2002 as determined by dN/dS ratios and IA valuesa
|

DISCUSSION
A number of studies have been performed with collections of
meningococci that cause disease (
6,
9,
11,
12,
22). This is
reflected by the large number of STs now present within the
MLST database. These studies, with which these STs are related,
have centered upon carriage and disease, and have been performed
mostly during time periods where the selective pressures are
normal (i.e., outside of vaccine programs). Our study has taken
all available invasive isolates over a 4-year period, starting
prior to the implementation of MenC vaccines in the United Kingdom
and then continuing through the following 3-year period after
vaccine implementation, to determine the genetic diversity of
the disease-causing meningococcal population. We have shown
that the genetic diversity of disease-causing meningococci has
significantly increased after the introduction of MenC vaccines
and that this increase has reflected a significant decrease
in serogroup C ET-37/ST-11 meningococci which has not been accompanied
by an increase in serogroup B meningococci of the same genetic
lineage. The diversity of the current disease-causing meningococcal
population is due, however, to the presence of new combinations
of alleles arising from recombination, thus pertaining to new
ST profiles rather than allele mutation. The increase in recombination
between years 1 to 4 may therefore be due to natural selection
and the increased ability of non-ST-11 meningococci to fill
the niche left by this clone. Interestingly, this niche has
been filled by meningococci of numerous STs and from a number
of clonal complexes. Currently, therefore, there is no hyperendemic
clone present in the United Kingdom that has directly replaced
the ST-11 clone. However, some clones, such as the ST-269 clone,
must be monitored closely, as they have increased year by year
since 1999. Our findings will have an important impact on conjugate
vaccine strategy for the control of meningococcal disease, as
well as other bacterial pathogens, because the medium to long-term
effects of vaccines directed against a single serogroup clearly
have an effect on the meningococcal population biology. Although
the introduction of MenC vaccines has not led directly to serogroup
switching (to serogroup B), a definite increase in numbers of
clones of serogroup B has been observed, although much of this
may be due to the typical cyclical pattern of serogroup B/C
incidence. Further retrospective and prospective studies must
therefore be performed in order to gain further insights into
the whole meningococcal population, not just that causing invasive
disease, including the emergence of important genetic lineages.
Although, in the present study, we included meningococci from
almost 1 full year prior to the introduction of the MenC vaccine,
analysis of disease-causing isolates in additional years prior
to vaccine implementation would be useful. Our laboratory is
currently analyzing such data from a 30-year period prior to
implementation of the MenC vaccine. Our data will also be merged
with meningococcal carriage study data so that the relationship
between carriage and disease can be better understood.

ACKNOWLEDGMENTS
We thank all members of the SMPRL for their general support,
as well as Tim Mitchell, Glasgow University, Martin Maiden,
Oxford University, and Brian Spratt, Imperial College, for useful
comments. This publication made use of the Neisseria Multi Locus
Sequence Typing and SMPRL MLST websites (
http://neisseria.mlst.net and
http://phoenix.medawar.ox.ac.uk/smprl) developed by Man-Suen
Chan and Keith Jolley and sited at the University of Oxford.
The development of this site has been funded by the Wellcome
Trust and European Union.
Our laboratory is funded by the Meningitis Association (Scotland), Chief Scientist's Office of the Scottish Executive and National Services Division of the Scottish Executive.

FOOTNOTES
* Corresponding author. Present address: Dept. of Improving Health and Quality, Portsmouth City PCT, Finchdean House, Milton Road, Portsmouth PO3 6DP, United Kingdom. Phone: 44 23 9283 5020. Fax: 44 23 9723 3292. E-mail:
stuartcclarke{at}hotmail.com.


REFERENCES
1 - Ada, G., and D. Isaacs. 2003. Carbohydrate-protein conjugate vaccines. Clin. Microbiol. Infect. 9:79-85.[CrossRef][Medline]
2 - Balmer, P., R. Borrow, and E. Miller. 2002. Impact of meningococcal C conjugate vaccine in the UK. J. Med. Microbiol. 51:717-722.[Abstract/Free Full Text]
3 - Brown, A. H., M. W. Feldman, and E. Nevo. 1980. Multilocus structure of natural populations of Hordeum spontaneum. Genetics 96:523-536.[Abstract/Free Full Text]
4 - Chan, M. S., M. C. Maiden, and B. G. Spratt. 2001. Database-driven multi locus sequence typing (MLST) of bacterial pathogens. Bioinformatics 17:1077-1083.[Abstract/Free Full Text]
5 - Clarke, S. C., P. Christie, and G. F. Edwards. 1999. Enhanced surveillance of meningococcal disease in Scotland. SCIEH Wkly. Rep. 33:235-236.
6 - Clarke, S. C., M. A. Diggle, and G. F. Edwards. 2001. Semiautomation of multilocus sequence typing for the characterization of clinical isolates of Neisseria meningitidis. J. Clin. Microbiol. 39:3066-3071.[Abstract/Free Full Text]
7 - Clarke, S. C., J. Reid, L. Thom, B. C. Denham, and G. F. Edwards. 2002. Laboratory confirmation of meningococcal disease in Scotland, 1993-9. J. Clin. Pathol. 55:32-36.[Abstract/Free Full Text]
8 - Diggle, M. A., and S. C. Clarke. 2002. Rapid assignment of nucleotide sequence data to allele types for multi-locus sequence analysis (MLSA) of bacteria using an adapted database and modified alignment program. J. Mol. Microbiol. Biotechnol. 4:515-517.[CrossRef][Medline]
9 - Feil, E. J., M. C. Maiden, M. Achtman, and B. G. Spratt. 1999. The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol. Biol. Evol. 16:1496-1502.[Abstract]
10 - Jolley, K. A., E. J. Feil, M. S. Chan, and M. C. Maiden. 2001. Sequence type analysis and recombinational tests (START). Bioinformatics 17:1230-1231.[Abstract/Free Full Text]
11 - Jolley, K. A., J. Kalmusova, E. J. Feil, S. Gupta, M. Musilek, P. Kriz, and M. C. Maiden. 2000. Carried meningococci in the Czech Republic: a diverse recombining population. J. Clin. Microbiol. 38:4492-4498.[Abstract/Free Full Text]
12 - Maiden, M. C., J. A. Bygraves, E. Feil, G. Morelli, J. E. Russell, R. Urwin, Q. Zhang, J. Zhou, K. Zurth, D. A. Caugant, I. M. Feavers, M. Achtman, and B. G. Spratt. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. USA 95:3140-3145.[Abstract/Free Full Text]
13 - Maiden, M. C., and J. M. Stuart. 2002. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359:1829-1831.[CrossRef][Medline]
14 - Mooney, J. D., P. Christie, C. Robertson, and S. C. Clarke. 2004. The impact of meningococcal serogroup C conjugate vaccine in Scotland. Clin. Infect. Dis. 39:349-356.[Medline]
15 - Nei, M., and T. Gojobori. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3:418-426.[Abstract]
16 - Ramsay, M., E. Kaczmarski, M. Rush, R. Mallard, P. Farrington, and J. White. 1997. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun. Dis. Rep. CDR Rev. 7:R49-R54.[Medline]
17 - Ramsay, M. E., N. Andrews, E. B. Kaczmarski, and E. Miller. 2001. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357:195-196.[CrossRef][Medline]
18 - Ramsay, M. E., N. J. Andrews, C. L. Trotter, E. B. Kaczmarski, and E. Miller. 2003. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 326:365-366.[Free Full Text]
19 - Rappuoli, R. 2001. Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 19:2319-2322.[CrossRef][Medline]
20 - Rosenstein, N. E., M. Fischer, and J. W. Tappero. 2001. Meningococcal vaccines. Infect. Dis. Clin. N. Am. 15:155-169.[CrossRef][Medline]
21 - Smith, J. M., N. H. Smith, M. O'Rourke, and B. G. Spratt. 1993. How clonal are bacteria? Proc. Natl. Acad. Sci. USA 90:4384-4388.[Abstract/Free Full Text]
22 - Tzanakaki, G., R. Urwin, M. Musilek, P. Kriz, J. Kremastinou, A. Pangalis, C. C. Blackwell, and M. C. Maiden. 2001. Phenotypic and genotypic approaches to characterization of isolates of Neisseria meningitidis from patients and their close family contacts. J. Clin. Microbiol. 39:1235-1240.[Abstract/Free Full Text]
23 - Vogel, U., and H. Claus. 2003. Molecular epidemiology of Neisseria meningitidis. Front. Biosci. 8:E14-E22.
24 - Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, N. M. Bennett, R. Lynfield, A. Reingold, P. R. Cieslak, T. Pilishvili, D. Jackson, R. R. Facklam, J. H. Jorgensen, and A. Schuchat. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746.[Abstract/Free Full Text]
Journal of Clinical Microbiology, September 2005, p. 4649-4653, Vol. 43, No. 9
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.9.4649-4653.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Taha, M.-K., Vazquez, J. A., Hong, E., Bennett, D. E., Bertrand, S., Bukovski, S., Cafferkey, M. T., Carion, F., Christensen, J. J., Diggle, M., Edwards, G., Enriquez, R., Fazio, C., Frosch, M., Heuberger, S., Hoffmann, S., Jolley, K. A., Kadlubowski, M., Kechrid, A., Kesanopoulos, K., Kriz, P., Lambertsen, L., Levenet, I., Musilek, M., Paragi, M., Saguer, A., Skoczynska, A., Stefanelli, P., Thulin, S., Tzanakaki, G., Unemo, M., Vogel, U., Zarantonelli, M. L.
(2007). Target Gene Sequencing To Characterize the Penicillin G Susceptibility of Neisseria meningitidis. Antimicrob. Agents Chemother.
51: 2784-2792
[Abstract]
[Full Text]
-
Fusco, P. C., Farley, E. K., Huang, C.-H., Moore, S., Michon, F.
(2007). Protective Meningococcal Capsular Polysaccharide Epitopes and the Role of O Acetylation. CVI
14: 577-584
[Abstract]
[Full Text]
-
Law, D. K. S., Lorange, M., Ringuette, L., Dion, R., Giguere, M., Henderson, A. M., Stoltz, J., Zollinger, W. D., De Wals, P., Tsang, R. S. W.
(2006). Invasive Meningococcal Disease in Quebec, Canada, Due to an Emerging Clone of ST-269 Serogroup B Meningococci with Serotype Antigen 17 and Serosubtype Antigen P1.19 (B:17:P1.19).. J. Clin. Microbiol.
44: 2743-2749
[Abstract]
[Full Text]